Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740223 | 1.00 | HTR1A (0.35) | HTR1AHCRTR2ADRA1AACACBCARM1 | |
| SCHEMBL18722013 | 0.93 | ADRA1A (0.35) | ADRA1A | |
| SCHEMBL12733657 | 0.93 | ADRA1A (0.35) | ADRA1A | |
| SCHEMBL12740191 | 0.91 | HTR1A (0.36) | HTR1AHCRTR2ACACBCARM1PRMT6 | |
| SCHEMBL12736580 | 0.91 | HTR1A (0.36) | HTR1AHCRTR2ACACBCARM1PRMT6 | |
| SCHEMBL12736651 | 0.90 | HTR1A (0.32) | HTR1AHCRTR2ADRA1A | |
| SCHEMBL13586216 | 0.90 | HTR1A (0.35) | HTR1AHCRTR2ADRA1AACACBCARM1 | |
| SCHEMBL12719280 | 0.90 | HTR1A (0.35) | HTR1AHCRTR2ADRA1AACACBCARM1 | |
| SCHEMBL13586567 | 0.90 | HTR1A (0.35) | HTR1AHCRTR2ADRA1AACACBCARM1 | |
| SCHEMBL12823280 | 0.90 | HTR1A (0.35) | HTR1AHCRTR2ADRA1AACACBCARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | HTR1A 484/4885HCRTR2 730/4885ADRA1A 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.